Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Clinical Trials Related to Zanidatamab
Related studies linked through entity extraction aliases.
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
- Status
- RECRUITING
- Phase
- PHASE2
AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas
- Status
- RECRUITING
- Phase
- PHASE2
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
- Status
- RECRUITING
- Phase
- PHASE2
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
PRE-I-SPY Phase I/Ib Oncology Platform Program
- Status
- RECRUITING
- Phase
- PHASE1
Personalized Medicine for Advanced Biliary Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- Status
- RECRUITING
- Phase
- PHASE2